ELISpot & FluoroSpot Assay Market by Product (Acessories, Analyzers, Assay Kits), Application (Autoimmune Disorders, Infectious Diseases, Oncology), End-User - Global Forecast 2024-2030

ELISpot & FluoroSpot Assay Market by Product (Acessories, Analyzers, Assay Kits), Application (Autoimmune Disorders, Infectious Diseases, Oncology), End-User - Global Forecast 2024-2030

The ELISpot & FluoroSpot Assay Market size was estimated at USD 292.68 million in 2023 and expected to reach USD 313.61 million in 2024, at a CAGR 7.02% to reach USD 470.74 million by 2030.

ELISpot (enzyme-linked immunosorbent spot) assays are sensitive and potent immunoassays that measure the quantity of antigen-specific T cells by evaluating the number of cytokine-secreting cells. FluoroSpot assays can visualize and enumerate the number of polyfunctional T cells and single-cytokine producers. FluoroSpot assay uses fluorescent labels with discrete, non-overlapping wavelengths to differentiate individual cytokines and co-secreted cytokines. Both ELISPOT and fluoroSpot assays are widely used in immuno-monitoring of clinical trials where both quantitative information and T cell phenotype identification at a single cell level are required. The rising increasing prevalence of chronic diseases across the world and a surge in biomedical research have necessitated the deployment of robust immunological assays for diagnosis and monitoring. Furthermore, the rise in investments in the pharmaceutical and biotechnology sectors, driven by a growing focus on personalized medicine, has expanded the application scope of these assays. However, the complexity of operating the assay and the chances of variability in test results impede the widespread adoption of the assays. Additionally, the difficulty of interpretation of test results and data analysis complexities with ELISpot & FluoroSpot assays further pose complications for utilization of ELISpot and FluoroSpot. However, the healthcare industry's continuous push toward innovation coupled with R&D initiatives aimed towards improving the specificity and accuracy of the assays can overcome the technical constraints of using ELISpot and FluoroSpot assay. A growing emphasis on immunotherapy treatments for cancer and other diseases further creates a significant need for ELISpot and FluoroSpot assays.

Regional Insights

The continued growth of ELISpot and FluoroSpot assays in the Americas region can be credited to its well-established healthcare and biotechnological sectors, significant investments in research and development, and the presence of major market players. Particularly, the United States, with a robust healthcare infrastructure and increased healthcare spending, is driving the growth in this region. Europe is another key region for the ELISpot and FluoroSpot assays, with countries such as Germany, the United Kingdom, France, and Italy leading the growth of the technology. The growth in Europe is driven by advanced healthcare systems and the presence of reputed research institutions. Moreover, collaborations between academic institutions and the industry foster innovation in assay development. The European market also benefits from supportive regulatory policies aimed towards the development of advanced ELISpot and FluoroSpot assays. In the APAC region, the need for ELISpot and FluoroSpot assays is expanding due to increased awareness regarding advanced immunodiagnostic techniques, increased awareness about chronic diseases, and government initiatives aimed at enhancing healthcare outcomes. Furthermore, the presence of contract research organizations (CROs) in this region positions the Asia Pacific as a prominent region for the growth of both assays.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the ELISpot & FluoroSpot Assay Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Increasing prevalence of chronic and infectious diseases
Rising need for immunotherapy and personalized medicines
Growing usage owing to an increase in immune monitoring studies

Market Restraints

Complexity and variability of assay protocols

Market Opportunities

Advancements in the development of user-friendly and high-throughput assay systems
High potential of eLISpot & fluoroSpot assay in veterinary applications

Market Challenges

Interpretation and data analysis complexities with eLISpot & fluoroSpot assays

Market Segmentation Analysis

Product: Growing preference for comprehensive assay kits among research institutions and laboratories
Application: Expanding government initiatives to propel oncology research, diagnosis, and therapy
End-user: Pertaining use of ELISpot & FluoroSpot assays in research and clinical practices providing unprecedented accuracy and reliable results

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the ELISpot & FluoroSpot Assay Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the ELISpot & FluoroSpot Assay Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Singamaneni to develop advanced protein imaging method

McKelvey School of Engineering at Washington University in St. Louis received a grant of USD 450,000 from the National Science Foundation to develop a method called Plasmon-Enhanced Expansion FluoroSpot (PEEFS) to address the difficulty of discerning individual cell behaviors and differences. PEEFS combines a very bright fluorescent nanoparticle with expansion microscopy to image secreted proteins with high sensitivity and precision and accurately measure minute cell differences.

Celerion Expands Its Service Offering to Include GLP/GCP Compliant Molecular and Cell Biology Testing

Celerion, a contract research organization (CRO), enhanced its molecular and cellular capabilities to adhere to Good Laboratory Practice and Good Clinical Practice (GLP/GCP) standards. This expansion encompasses various advanced techniques, including ELISpot & FluoroSpot Assay, flow cytometry, and qPCR analyses. These additions enable Celerion to provide comprehensive and high-quality services to its clients in the biopharmaceutical sector.

PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer's Oxford Immunotec has obtained FDA approval for its T-Cell Select reagent kit, which allows certified laboratories to automate the workflow of the T-SPOT.TB test. The T-Cell Select reagent material facilitates the positive selection of peripheral blood mononuclear cells (PBMCs) through magnetic bead-based cell separation. This approved kit streamlines the preparation of cells for the T-SPOT.TB test, an ELISPOT Interferon-Gamma Release Assays (IGRA) that detects latent TB infection, thereby ensuring compliance with global regulations.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the ELISpot & FluoroSpot Assay Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the ELISpot & FluoroSpot Assay Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Anogen-Yes Biotech Laboratories Ltd, Autoimmun Diagnostika GmbH, Becton, Dickinson and Company, Bio-Techne Corporation, BIOSYS Scientific Devices GmbH, BOC Sciences, Broughton Life Sciences Limited, CellCarta Biosciences Inc., Creative Proteomics, Elabscience, Full Moon BioSystems, Inc., Jackson ImmunoResearch Inc., Mabtech AB, Merck KGaA, Oxford Immunotec USA, Inc., Oy Medix Biochemica Ab, ProImmune Ltd., Quansys Biosciences Inc., SBH Sciences, U-CyTech BV, and ZenBio, Inc..

Market Segmentation & Coverage

This research report categorizes the ELISpot & FluoroSpot Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Acessories
Analyzers
Assay Kits
Application
Autoimmune Disorders
Infectious Diseases
Oncology
Organ Transplantation
Vaccine Development
End-User
Academic Research Institutes
Hospitals & Clinical Laboratories
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year